Sernova company

Sernova Corp., a health sciences company, focuses on the development and commercialization of medical technologies in the United States and Canada. Its proprietary platform technologies include Cell Pouch System, a device providing a natural organ-like environment for therapeutic cells, such as insulin producing islets for diabetics; and Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. The company also focuses to commercialize products for the treatment of Parkinson’s, spinal cord injury, and haemophilia diseases. Sernova Corp. is headquartered in London, Canada.
Technology: Regenerative Medicine
Industry: Personalized Medicine
Headquarters: London, England, United Kingdom
Founded Date: Undisclosed
Employees Number: 1-10
Funding Status: IPO
Total Funding: $6.2M
Estimated Revenue: $100M to $500M
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership